Strid Group’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Strid Group’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-18,000	Closed	-$77K	–	31
2017 Q4	$77K	Buy	+18,000	New	+$85.8K	0.03%	30

Other funds holding ECYT

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Associates

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Strid Group's ECYT Position: Q1 2018 in Review

Strid Group sold out of Endocyte, Inc. Common Stock (ECYT) in Q1 2018, closing a stake of 18,000 shares — an estimated $77K sold.

Strid Group first reported a position in ECYT in Q4 2017 and held it in 1 quarter. The position peaked at $77K in Q4 2017. 89 funds tracked by Wall St. Rank hold ECYT as of Q1 2018.

Strid Group reported no remaining Endocyte, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Strid Group sold 18,000 Endocyte, Inc. Common Stock shares in Q1 2018, an estimated $77K.
Strid Group first reported a position in Endocyte, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
Strid Group's Endocyte, Inc. Common Stock position peaked at $77K in Q4 2017.
89 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q1 2018.

Based on Strid Group's 13F filing for Q1 2018, filed 20 Apr 2018.